In November 1998, Stephen Briggs was appointed Director General of Novartis Agricultural Discovery Institute, Inc (NADII), a new research institute was created under the auspices of corporate Novartis AG. NADII has a mandate to encourage basic research program Novartis plant genomics and Briggs examines recent studies offer the terms offered by the University of California, Berkeley (UC Berkeley). Novartis was a finalist in the auction started at the university in April 1998 to find a corporate partner, with whom she could establish a broad alliance of plant genomics research. The agreement was unprecedented and requires a lot of trust on the part of Novartis - trust that Berkeley faculty can make useful discoveries for the young company's plant genomics initiative. At first glance, it seemed that the recent advances in high-priced areas of life sciences, combined with the heated competition in the industry for leadership in the field of biotechnology, tied the interests of the University and Novartis. Briggs was ready to accept the offer. Before the pen to paper, but, in his view, the forces that led to the historic agreement between Novartis and the University of California at Berkeley, research results, the strategic choice of the firm, and the contribution of the scientific community to new discoveries. "Hide
by Margaret L. Eaton Source: Stanford Graduate School of Business 25 pages. Publication Date: April 1, 2004. Prod. #: BME7-PDF-ENG